Loading…
Rural Opioid Abuse Prevention Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
98pct
454d open
vs 5,357 other S bills in the 117th — cohort avg 38d
Rural Opioid Abuse Prevention Act This act expands the allowable uses of grant funds under the Comprehensive Opioid, Stimulant, and Substance Abuse Program administered by the Department of Justice. Specifically, the act allows grants to be used for pilot programs for rural areas to implement community response programs that focus on reducing opioid overdose deaths, which may include presenting alternatives to incarceration.
Yes
408
No
11
Present
0
Not Voting
12
Party Breakdown
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2022 · fourth_quarter · Health Issues
Medication safety, pharmacy regulation and licensure, and the opioid epidemic; Prescription drug monitoring programs; COVID-19 response; H.R.2482, S. 2074 - Mainstreaming Addiction Treatment Act; Prescription drug importation; H.R. 6352, S. 3399 - Domain Reform for Unlawful Drug Sellers Act; S. 2796/H.R. 2985 Rural Opioid Abuse Prevention Act; H.R. 2355 Opioid Prescription Verification Act; H.R. 2617 Consolidated Appropriations Act.
Client expense: Not reported · Firm income: $30,000
Became Public Law No: 117-250.
Became Public Law No: 117-250.
Signed by President.
Signed by President.
Presented to President.
Presented to President.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 408 - 11 (Roll no. 509). (text: 12/05/2022 CR H8745)
HousePassed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by the Yeas and Nays: (2/3 required): 408 - 11 (Roll no. 509).
HouseConsidered as unfinished business. (consideration: CR H8771-8773; H8778)
Bills with similar content found using semantic analysis.
Sources: Congress.gov · House Clerk roll-call votes
| house |
| On Motion to Suspend the Rules and Pass |
Passed |
| December 6, 2022 |
Government targets: Drug Enforcement Administration (DEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE
2022 · fourth_quarter · Pharmacy
Medication safety, pharmacy regulation and licensure, and the opioid epidemic; Prescription drug monitoring programs; COVID-19 response; H.R.2482, S. 2074 - Mainstreaming Addiction Treatment Act; Prescription drug importation; H.R. 6352, S. 3399 - Domain Reform for Unlawful Drug Sellers Act; S. 2796/H.R. 2985 Rural Opioid Abuse Prevention Act; H.R. 2355 Opioid Prescription Verification Act; H.R. 2617 Consolidated Appropriations Act.
Client expense: Not reported · Firm income: $30,000
Government targets: Drug Enforcement Administration (DEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE
2022 · third_quarter · Pharmacy
Medication safety, pharmacy regulation and licensure, and the opioid epidemic; Prescription drug monitoring programs; COVID-19 response; H.R.2482, S. 2074 - Mainstreaming Addiction Treatment Act; Prescription drug importation; H.R. 6352, S. 3399 - Domain Reform for Unlawful Drug Sellers Act; S. 2796/H.R. 2985 Rural Opioid Abuse Prevention Act; H.R. 2355 Opioid Prescription Verification Act.
Client expense: Not reported · Firm income: $30,000
Government targets: Drug Enforcement Administration (DEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE
2022 · third_quarter · Health Issues
Medication safety, pharmacy regulation and licensure, and the opioid epidemic; Prescription drug monitoring programs; COVID-19 response; H.R.2482, S. 2074 - Mainstreaming Addiction Treatment Act; Prescription drug importation; H.R. 6352, S. 3399 - Domain Reform for Unlawful Drug Sellers Act; S. 2796/H.R. 2985 Rural Opioid Abuse Prevention Act; H.R. 2355 Opioid Prescription Verification Act.
Client expense: Not reported · Firm income: $30,000
Government targets: Drug Enforcement Administration (DEA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
DEBATE - The House proceeded with forty minutes of debate on S. 2796.
Considered under suspension of the rules. (consideration: CR H8745-8750)
Ms. Jackson Lee moved to suspend the rules and pass the bill.
Held at the desk.
Received in the House.
Message on Senate action sent to the House.
Passed Senate with an amendment by Unanimous Consent. (text: CR S9041)
Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.(text: CR S9041)
Measure laid before Senate by unanimous consent. (consideration: CR S9041)
Senate Committee on the Judiciary discharged by Unanimous Consent.
Senate Committee on the Judiciary discharged by Unanimous Consent.
Read twice and referred to the Committee on the Judiciary.
Introduced in Senate
| -- |